Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-28

Study Completion Date

2023-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to use qualitative interviews to elicit and confirm concepts related to treatment preferences and understandability of the pTPMQ, cTPMQ, and mTPMQ. The information gathered will be used to support the appropriateness of the questionnaires as a patient-reported, caregiver-reported and clinician-reported outcome measure (PROM) in the population of interest.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes

NCT00809575

Adult Myelodysplastic Syndromes

UNKNOWN

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers

NCT06987708

Monoclonal Gammopathy of Uncertain Significance Smoldering Myeloma

NOT_YET_RECRUITING NA

Examination of Trends in Multiple Myeloma Trial Patient Experiences

NCT05860179

Multiple Myeloma

NOT_YET_RECRUITING

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

NCT01099267

Myelodysplastic Syndrome

COMPLETED

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

NCT00242827

Myeloma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndrome (MDS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient

Patients with MDS

Patient Treatment Preference Myelodysplasia Questionnaire

Intervention Type OTHER

Patient-reported outcome measure (PROM) in MDS

Carer

Carers of patients with MDS

Carer Treatment Preference Myelodysplasia Questionnaire

Intervention Type OTHER

Caregiver-reported outcome measure in MDS

Clinician

Clinicians who treat MDS

Clinician Treatment Preference Myelodysplasia Questionnaire

Intervention Type OTHER

Clinician-reported outcome measure in MDS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carer Treatment Preference Myelodysplasia Questionnaire

Caregiver-reported outcome measure in MDS

Intervention Type OTHER

Clinician Treatment Preference Myelodysplasia Questionnaire

Clinician-reported outcome measure in MDS

Intervention Type OTHER

Patient Treatment Preference Myelodysplasia Questionnaire

Patient-reported outcome measure (PROM) in MDS

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

A. Adult patients with myelodysplastic syndrome meeting any one of the following criteria:

1. They are currently being treated with azacitidine or
2. They have recently been treated with azacitidine or
3. They have been deemed eligible for treatment with azacitidine, but have not yet commenced treatment

Exclusion Criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

A. Patients meeting any of the following criteria are excluded:

1. They have lower risk disease (international prognostic scoring system low or intermediate-1 risk)
2. Cognitive or physical impairment of a nature that makes it infeasible for them to effectively participate in a structured interview.
3. Deemed appropriate for stem cell transplantation and are being pre-treated or will be treated with azacitidine
4. They were treated, are being treated, or will be treated with azacitdine as part of a clinical trial
5. They are a relative of an employee of the investigational clinic, sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).

B. Carers meeting any of the following criteria are excluded:

2. They are a relative of an employee of the investigational clinic, sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).

C. Clinician will be excluded from participating in the study if a relative of an employee of the sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).

D. Participants who are not fluent in English, or who cannot read or write in English will be excluded from the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No